公开(公告)号：US11952428B2

公开(公告)日：2024-04-09

申请号：US18170941

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20230416390A1

公开(公告)日：2023-12-28

申请号：US18184860

申请日：2023-03-16

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: C07K16/2878 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20190292238A1

公开(公告)日：2019-09-26

申请号：US16256731

申请日：2019-01-24

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hans Bitter ,  Jennifer Mary Bordeaux ,  Barbara Brannetti ,  Jennifer Brogdon ,  Naveen Kumar Dakappagari ,  Saar Gill ,  Steven Highfill ,  Lu Huang ,  Carl H. June ,  Ju Young Kim ,  Ming Lei ,  Na Li ,  Andreas Loew ,  Elena Orlando ,  Marco Ruella ,  Thai Tran ,  Jimin Zhang ,  Li Zhou

IPC: C07K14/705 ,  A61K39/00 ,  C07K16/28 ,  C07K14/725 ,  A61K45/06

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.